{"id":390320,"date":"2019-12-04T00:00:00","date_gmt":"2019-12-04T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0007-2019-biopharma-non-small-cell-lung-cancer-disease-landscape-and-forecast-g7-2019\/"},"modified":"2026-04-18T11:37:04","modified_gmt":"2026-04-18T11:37:04","slug":"dlsfon0007-2019-biopharma-non-small-cell-lung-cancer-disease-landscape-and-forecast-g7-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0007-2019-biopharma-non-small-cell-lung-cancer-disease-landscape-and-forecast-g7-2019\/","title":{"rendered":"Non-Small-Cell Lung Cancer | Disease Landscape and Forecast | G7 | 2019"},"content":{"rendered":"<p>Non-small-cell lung cancer (<abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr>) is one of the most dynamic oncology indications and a key area of focus for drug developers. Immune checkpoint inhibitors have transformed the management of advanced\u00a0<abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr>. In late 2018, Tecentriq (Roche \/ Genentech \/ Chugai) was the second immune checkpoint inhibitor to enter the coveted first-line metastatic setting, after Keytruda (Merck &#038; Co.). Competition is set to intensify as multiple combination therapies based on immune checkpoint inhibition gain approval and enter the clinic. In addition, novel biomarker-driven therapies such as next-generation\u00a0<abbr title=\"epidermal growth factor receptor\">EGFR<\/abbr>\u00a0and\u00a0<abbr title=\"anaplastic lymphoma kinase\">ALK<\/abbr>\u00a0inhibitors are vying for a share of this increasingly crowded and competitive market.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>How large are the drug-treatable\u00a0<abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr>\u00a0populations, and how will drug-treatment rates change over time in market-relevant populations?<\/li>\n<li>How will recent and expected market approvals shape the uptake of immune checkpoint inhibitors for the first-line treatment of metastatic\u00a0<abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr>? Which agents and combinations will dominate this commercially lucrative disease setting?<\/li>\n<li>What pipeline products are most promising, and what uptake and sales could they secure in\u00a0<abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr>? What therapies of note are progressing in earlier phases of development?<\/li>\n<li>What are the key market drivers and constraints in\u00a0<abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr>, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p><em>Disease Landscape &#038; Forecast<\/em>\u00a0provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Scope:<\/strong><\/p>\n<p><b>Markets covered:<\/b>\u00a0United States, France, Germany, Italy, Spain, United Kingdom, Japan.<\/p>\n<p><b>Primary research:<\/b>\u00a016 country-specific interviews with experts and 210 country-specific surveys with medical oncologists treating\u00a0<abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr>.<\/p>\n<p><b>Epidemiology:<\/b>\u00a0Diagnosed and recurrent incidence of adenocarcinoma, squamous cell carcinoma, large cell carcinoma and other, and unverified\u00a0<abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr>.<\/p>\n<p><b>Population segments in market forecast:<\/b>\u00a0Stage IB\/II, stage III, first line, second line, and third line for metastatic adenocarcinoma, squamous cell carcinoma, large cell carcinoma and other, and unverified\u00a0<abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr>.<\/p>\n<p><b>Emerging therapies:\u00a0<\/b>Phase I\/II: 13 drugs; Phase III \/\u00a0<abbr title=\"preregistered\">PR<\/abbr>: 17 drugs.<\/p>\n","protected":false},"template":"","class_list":["post-390320","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-non-small-cell-lung-cancer","biopharma-therapy-areas-small-cell-lung-cancer","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390320","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390320\/revisions"}],"predecessor-version":[{"id":576574,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390320\/revisions\/576574"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390320"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}